Nabla Bio
Generative AI for de novo antibody design
Nabla Bio's JAM (Joint Atomic Modeling) platform achieves breakthrough hit rates in de novo antibody design. JAM-2 demonstrated 100% hit rate across 16 unseen targets, with picomolar binders on 50% of targets — including the first computationally designed antibody agonists for CXCR7. The company has secured $550M+ in pharma milestones from AstraZeneca, Bristol-Myers Squibb, and Takeda.
Antibody Design, Generative Chemistry, Foundation Models
JAM, JAM-2
Funding
$37M
Total raised
Radical Ventures · Khosla Ventures · Zetta Venture Partners
Technology
JAM (Joint Atomic Modeling) platform — 'molecular auto-complete' for antibody design. JAM-2 generates binders for 100% of unseen targets tested, producing picomolar/single-digit nanomolar affinities on 50% of targets. Designed first antibody agonists for CXCR7.
Leadership
Surge Biswas
CEO & Co-Founder
Harvard PhD; AI and protein design
Partnerships
Similar companies
Generate:Biomedicines
Generative AI for de novo protein therapeutic design
preclinical · 2020Xaira Therapeutics
AI-native drug discovery with $1B+ launch — largest in biotech history
preclinical · 2024Latent Labs
Making biology programmable with generative AI
platform · 2025Absci Corporation
AI-powered de novo antibody design and creation
preclinical · 2011Get updates on Nabla Bio
We'll notify you when we publish updates about Nabla Bio.